Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART

Antiviral Research

Volumn 61, Issue 3, 2004, Pages 207-212

  Wasmuth, Jan Christian ^a   Nischalke, Hans Dieter ^a   Jütte, Alexander ^b   Fätkenheuer, Gerd ^b   Salzberger, Bernd ^c   Sauerbruch, Tilman ^a   Spengler, Ulrich ^a   Rockstroh, Jürgen K ^a   Dumoulin, Franz L ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Antiretrovirals; Chemokine mRNA levels; HIV; Mononucleated cells; NNRTIs; PIs

Indexed keywords

BETA CHEMOKINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RANTES; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 0842268027     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2003.11.003     Document Type: Article

References (18)

1. Aleman S., Pehrson P., Sonnerborg A. Kinetics of beta-chemokine levels during anti-HIV therapy. Antiviral Ther. 4:1999;109-115.
2. Altfeld M., Addo M.M., Kreuzer K.A., Rockstroh J.K., Dumoulin F.L., Schliefer K., Leifeld L., Sauerbruch T., Spengler U. T(H)1 to T(H)2 shift of cytokines in peripheral blood of HIV-infected patients is detectable by reverse transcriptase polymerase chain reaction but not by enzyme-linked immunosorbent assay under nonstimulated conditions. J. Acquir. Immune Defic. Syndr. 23:2000;287-294.
3. Bart P.A., Rizzardi G.P., Tambussi G., Chave J.P., Chapuis A.G., Graziosi C., Corpataux J.M., Halkic N., Meuwly J.Y., Munoz M., Meylan P., Spreen W., McDade H., Yerly S., Perrin L., Lazzarin A., Pantaleo G. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. AIDS. 14:2000;1887-1897.
4. Bartlett J.A., DeMasi R., Quinn J., Moxham C., Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 15:2001;1369-1377.
5. Bisset L.R., Rothen M., Joller-Jemelka H.I., Dubs R.W., Grob P.J., Opravil M. Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 1 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS. 11:1997;485-491.
6. Burton C.T., Hardy G.A.D., Sullivan A.K., Nelson M.R., Gazzard B., Gotch F.M., Imami N. Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, β-chemokines and IL-16 secretion in HIV-1 infection. Clin. Exp. Immunol. 130:2002;286-292.
7. Bustin S.A. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J. Mol. Endocrinol. 29:2002;23-39.
8. Carpenter C.C., Fischl M.A., Hammer S.M., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Saag M.S., Schooley R.T., Thompson M.A., Vella S., Yeni P.G., Volberding P.A. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 280:1998;78-86.
9. Carter L.M., Peters B.S., Ellis B.A., Wolstencroft R.A. Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection. J. Infect. 41:2000;252-255.
10. Clerici M., Seminari E., Suter F., Castelli F., Pan A., Biasin M., Colombo F., Trabattoni D., Maggiolo F., Carosi G., Maserati R. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia. The Master Group. AIDS. 14:2000;109-116.
11. + T cells. Science. 270:1995;1811-1815.
12. Dumoulin F.L., Nischalke H.D., Leifeld L., von dem Bussche A., Rockstroh J.K., Sauerbruch T., Spengler U. Semi-quantification of human C-C chemokine mRNAs with reverse transcription/real-time PCR using multi-specific standards. J. Immunol. Methods. 241:2000;109-119.
13. Giovannetti A., Ensoli F., Mazzetta F., De Cristofaro M., Pierdominici M., Muratori D.S., Fiorelli V., Aiuti F. CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy. Clin. Exp. Immunol. 118:1999;87-94.
14. Havlir D.V., Bassett R., Levitan D., Gilbert P., Tebas P., Collier A.C., Hirsch M.S., Ignacio C., Condra J., Gunthard H.F., Richman D.D., Wong J.K. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 286:2001;171-179.
15. McKenzie S.W., Dallalio G., North M., Frame P., Means R.T. Jr. Serum chemokine levels in patients with non-progressing HIV infection. AIDS. 10:1996;F29-F33.
16. Mengozzi M., De Filippi C., Transidico P., Biswas P., Cota M., Ghezzi S., Vicenzi E., Mantovani A., Sozzani S., Poli G. Human immunodeficiency virus replication induces monocyte chemotactic protein-1 in human macrophages and U937 promonocytic cells. Blood. 93:1999;1851-1857.
17. Nicastri E., Ercoli L., Sarmati L., d'Ettorre G., Iudicone P., Massetti P., Vullo V., Andreoni M. Human immunodeficiency virus-1 specific and natural cellular immunity in HIV seronegative subjects with multiple sexual exposures to virus. J. Med. Virol. 64:2001;232-237.
18. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., Stryker R., Johnson P., Labriola D.F., Farina D., Manion D.J., Ruiz N.M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New Engl. J. Med. 341:1999;1865-1873.